Insights into Potential Targets for Therapeutic Intervention in Epilepsy

Epilepsy is a chronic brain disease that affects approximately 65 million people worldwide. However, despite the continuous development of antiepileptic drugs, over 30% patients with epilepsy progress to drug-resistant epilepsy. For this reason, it is a high priority objective in preclinical researc...

Full description

Bibliographic Details
Main Authors: Cecilia Zavala-Tecuapetla, Manola Cuellar-Herrera, Hiram Luna-Munguia
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/22/8573
id doaj-a3d7abb82887485e9ace16e9a77f20ee
record_format Article
spelling doaj-a3d7abb82887485e9ace16e9a77f20ee2020-11-25T04:06:01ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-11-01218573857310.3390/ijms21228573Insights into Potential Targets for Therapeutic Intervention in EpilepsyCecilia Zavala-Tecuapetla0Manola Cuellar-Herrera1Hiram Luna-Munguia2. Laboratory of Physiology of Reticular Formation, National Institute of Neurology and Neurosurgery-MVS, Insurgentes Sur 3877, La Fama, 14269 Mexico City, Mexico. Epilepsy Clinic, Hospital General de México Dr. Eduardo Liceaga. Dr. Balmis 148, Doctores, 06720 Mexico City, Mexico. Departamento de Neurobiologia Conductual y Cognitiva, Instituto de Neurobiologia, Campus UNAM-Juriquilla, Universidad Nacional Autonoma de Mexico, 76230 Queretaro, MexicoEpilepsy is a chronic brain disease that affects approximately 65 million people worldwide. However, despite the continuous development of antiepileptic drugs, over 30% patients with epilepsy progress to drug-resistant epilepsy. For this reason, it is a high priority objective in preclinical research to find novel therapeutic targets and to develop effective drugs that prevent or reverse the molecular mechanisms underlying epilepsy progression. Among these potential therapeutic targets, we highlight currently available information involving signaling pathways (Wnt/β-catenin, Mammalian Target of Rapamycin (mTOR) signaling and zinc signaling), enzymes (carbonic anhydrase), proteins (erythropoietin, copine 6 and complement system), channels (Transient Receptor Potential Vanilloid Type 1 (TRPV1) channel) and receptors (galanin and melatonin receptors). All of them have demonstrated a certain degree of efficacy not only in controlling seizures but also in displaying neuroprotective activity and in modifying the progression of epilepsy. Although some research with these specific targets has been done in relation with epilepsy, they have not been fully explored as potential therapeutic targets that could help address the unsolved issue of drug-resistant epilepsy and develop new antiseizure therapies for the treatment of epilepsy.https://www.mdpi.com/1422-0067/21/22/8573epilepsyseizuresdrug-resistant epilepsyantiseizure efficacyantiepileptogenic effectneuroprotective effect
collection DOAJ
language English
format Article
sources DOAJ
author Cecilia Zavala-Tecuapetla
Manola Cuellar-Herrera
Hiram Luna-Munguia
spellingShingle Cecilia Zavala-Tecuapetla
Manola Cuellar-Herrera
Hiram Luna-Munguia
Insights into Potential Targets for Therapeutic Intervention in Epilepsy
International Journal of Molecular Sciences
epilepsy
seizures
drug-resistant epilepsy
antiseizure efficacy
antiepileptogenic effect
neuroprotective effect
author_facet Cecilia Zavala-Tecuapetla
Manola Cuellar-Herrera
Hiram Luna-Munguia
author_sort Cecilia Zavala-Tecuapetla
title Insights into Potential Targets for Therapeutic Intervention in Epilepsy
title_short Insights into Potential Targets for Therapeutic Intervention in Epilepsy
title_full Insights into Potential Targets for Therapeutic Intervention in Epilepsy
title_fullStr Insights into Potential Targets for Therapeutic Intervention in Epilepsy
title_full_unstemmed Insights into Potential Targets for Therapeutic Intervention in Epilepsy
title_sort insights into potential targets for therapeutic intervention in epilepsy
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-11-01
description Epilepsy is a chronic brain disease that affects approximately 65 million people worldwide. However, despite the continuous development of antiepileptic drugs, over 30% patients with epilepsy progress to drug-resistant epilepsy. For this reason, it is a high priority objective in preclinical research to find novel therapeutic targets and to develop effective drugs that prevent or reverse the molecular mechanisms underlying epilepsy progression. Among these potential therapeutic targets, we highlight currently available information involving signaling pathways (Wnt/β-catenin, Mammalian Target of Rapamycin (mTOR) signaling and zinc signaling), enzymes (carbonic anhydrase), proteins (erythropoietin, copine 6 and complement system), channels (Transient Receptor Potential Vanilloid Type 1 (TRPV1) channel) and receptors (galanin and melatonin receptors). All of them have demonstrated a certain degree of efficacy not only in controlling seizures but also in displaying neuroprotective activity and in modifying the progression of epilepsy. Although some research with these specific targets has been done in relation with epilepsy, they have not been fully explored as potential therapeutic targets that could help address the unsolved issue of drug-resistant epilepsy and develop new antiseizure therapies for the treatment of epilepsy.
topic epilepsy
seizures
drug-resistant epilepsy
antiseizure efficacy
antiepileptogenic effect
neuroprotective effect
url https://www.mdpi.com/1422-0067/21/22/8573
work_keys_str_mv AT ceciliazavalatecuapetla insightsintopotentialtargetsfortherapeuticinterventioninepilepsy
AT manolacuellarherrera insightsintopotentialtargetsfortherapeuticinterventioninepilepsy
AT hiramlunamunguia insightsintopotentialtargetsfortherapeuticinterventioninepilepsy
_version_ 1724432821121974272